Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
Tiffany Tang(SingHealth), Soon Thye Lim(National University of Singapore), Maica Yunon(National Cancer Centre Singapore), Cindy Lim(National Cancer Centre Singapore), Sean Xuexian Yan(Singapore General Hospital), Peter Martin(Northwestern University), Jason Yongsheng Chan(National Cancer Centre Singapore), Mohamad Farid(National Cancer Centre Singapore), Eileen Poon(National Cancer Centre Singapore), Nagavalli Somasundaram(National Cancer Centre Singapore), Miriam Tao(National Cancer Centre Singapore), Shu Q. Toh(National Cancer Centre Singapore)
Cited by 15
Related Papers
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
|Blood|2015|408
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
|Journal of Clinical Oncology|2009|340
Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
|Journal of Clinical Oncology|2010|319